Preclinical cellular pharmacology of LY231514 (MTA): A comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells

British Journal of Cancer

Volumn 78, Issue SUPPL. 1, 1998, Pages 27-34

  Chen, V J ^a   Bewley, J R ^a   Andis, S L ^a   Schultz, R M ^a   Iversen, P W ^a   Shih, C ^a   Mendelsohn, L G ^a   Seitz, D E ^a   Tonkinson, J L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antimetabolite; Multi targeted antifolate; Nucleotide

Indexed keywords

ADENOSINE TRIPHOSPHATE; DEOXYADENOSINE TRIPHOSPHATE; DEOXYCYTIDINE TRIPHOSPHATE; DEOXYGUANOSINE TRIPHOSPHATE; DIHYDROFOLIC ACID; FOLIC ACID; FOLIC ACID ANTAGONIST; GUANOSINE TRIPHOSPHATE; METHOTREXATE; N [5 [2 (2 AMINO 1,4,5,6,7,8 HEXAHYDRO 4 OXOPYRIDO[2,3 D]PYRIMIDIN 6 YL)ETHYL] 2 THENOYL]GLUTAMIC ACID; NUCLEOSIDE TRIPHOSPHATE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; RALTITREXED; THYMIDINE TRIPHOSPHATE; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; NUCLEIC ACID METABOLISM; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; METHOTREXATE; NUCLEOTIDES; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; QUINAZOLINES; REPRODUCIBILITY OF RESULTS; TETRAHYDROFOLATE DEHYDROGENASE; TETRAHYDROFOLATES; THIOPHENES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0031858217     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.751     Document Type: Review

References (43)

1. Ackland SP and Schilsky RL (1987) High-dose methotrexate: a critical reappraisal. J Clin Oncol 5: 2017-2031
2. Aherne GW, Hardcastle A, Raynaud F and Jackman AL (1996) Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of Tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Biochem Pharmacol 51: 1293-1301
3. Allegra CJ, Fine RL, Drake JC and Chabner BA (1986) The effect of methotrexate on intracelllular folate pools in human MCF-7 breast cancer cells: evidence for direct inhibition of purine synthesis. J Biol Chem 261: 6478-6485
4. Baram J, Allegra CJ, Fine RL and Chabner BA (1987) Effect of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow. J Clin Invest 79: 692-697
5. Benjamini Y and Hochberg V (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 57: 289-300
6. Chong L and Tattersall MHN (1995) 5,10-dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase. Biochem Pharmacol 49: 819-827
7. Clarke S, Boyer M, Millward M, Findlay M, Ackland S, Childs A, Brew S, Walcher V, Watt D and Campbell L (1997) Phase II study of LY231514 in patients with advanced non-small cell lung cancer (NSCLC). Am Soc Clin Oncol 16: abstract 1670
8. Cohen MB and Sadee W (1983) Contribution of the depletions of guanine and adenine nucleotides to the cytotoxicity of purine starvation in the mouse T lymphoma cell line. Cancer Res 43: 1587-1591
9. Cripps MC, Burnell M, Jolivet J, Lofters W, Fisher B, Panasci L, Iglesias J and Eisenhauer E (1997) Phase II study of a multi-targeted antifolate (LY231514) (MTA) as first-line therapy in patients with locally advanced or metastatic colorectal cancer (MCC). Am Soc Clin Oncol 16: abstract 949
10. Garrett C and Santi DV (1979) A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleotide triphosphates in cell extracts. Anal Biochem 99: 268-273
11. Habeck LL, Leitner TA, Shackelford KA, Gossett LS, Schultz RM, Andis SL, Shih C, Grindey GB and Mendelsohn LG (1994) A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumours. Cancer Res 54: 1021-1026
12. Habeck LL, Shih C, Gossett LS, Leitner TA, Schultz RM, Andis SL, Moran RG and Mendelsohn LG (1995) Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol 48: 326-333
13. Hanauske A-R (1996) The development of new chemotherapeutic agents. Anti-Cancer Drugs 7 (suppl.2): 29-32
14. Jackman AL and Calvert AH (1995) Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6: 871-881
15. Jackson RC (1992) The Theoretical Foundations of Cancer Chemotherapy introduced by Computer Models. Academic Press: San Diego, pp. 299-341
16. Jackson RC, Jackman AL and Calvert AH (1983) Biochemical effects of a quinazoline inhibitor of thymidylate synthase, N-(4-(N-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-L- glutamic acid (CB3717), on human lymphoblastoid cells. Biochem Pharmacol 32: 3783-3790
17. John W, Clark J, Burris H, Picus J, Schulman L, Thornton D and Lochrer P (1997) A phase II trial of LY231514 in patients with metastatic colorectal cancer. Am Soc Clin Oncol 16: abstract 1038
18. Kinahan JJ, Otten M and Grindey GB (1979) Evaluation of ribonucleoside and deoxyribonucleoside triphosphate pools in cultured leukemia cells during exposure to methotrexate or methotrexate plus thymidine. Cancer Res 39: 3531-3539
19. Kornberg A (1980) DNA Replication. WH Freeman: San Francisco
20. Kunz BA (1996) Inhibitors of thymine nucleotide biosynthesis: antimetabolites that provoke genetic change via primary non-DNA targets. Mutation Res 355: 129-140
21. Kwok JBJ and Tattersall MHN (1992) DNA fragmentation, dATP pool elevation and potentiation of antifolate cytotoxicity in L1210 cells by hypoxanthine. Br J Cancer 65: 503-508
22. Matherly LH and Muench SP (1990) Evidence for a localized conversion of endogenous tetrahydrofolate cofactors to dihydrofolate as an important element in antifolate action in murine leukemia cells. Biochem Pharmacol 39: 2005-2014
23. McDonald AC, Vasey PA, Walling J, Woodworm JR, Abrahams T, Bailey NP, Siddiqui N, Lind MJ, Cassidy J and Twelves CJ (1996) Phase 1 and pharmacokinetic study of LY231514, the multi-targeted antifolate, administered by daily x5, q21 schedule. Ann Oncol 7 (suppl. 5): 608P
24. Mendelsohn LG, Shih C, Schultz RM and Worzalla JF (1996) Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitor: LY309887 and lometrexol. Invest New Drugs 14: 287-294
25. Miller KD, Loehrer PJ, Picus J, Blanke C, John J, Shulman L, Burris H and Thornton D (1997) A phase II trial of LY231514 in patients with unresectable pancreatic cancer. Am Soc Clin Oncol 16: abstract 1060
26. Morrison PF and Allegra CJ (1989) Folate cycle kinetics in human breast cancer cells. J Biol Chem 264: 10552-10566
27. Newman EM and Santi DV (1982) Metabolism and mechanism of action of 5-fluorodeoxycytidine. Proc Natl Acad Sci USA 79: 6419-6423
28. Oliva FJ, Collins MKL and Lopez-Rivas A (1996) dNTP pools imbalance as a signal to initiate apoptosis. Experientia 52: 995-1000
29. Pizzomo G, Moroson BA, Cashmore AR and Beardsley GP (1991) (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells. Cancer Res 51: 2291-2295
30. Reichard P (1988) Interaction between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem 57: 349-374
31. Rinaldi DA, Burris HA, Dorr FA, Woodworm JR, Kuhn JG, Eckardt JR, Rodriguez G, Corso SW, Fields SM, Langley C, Clark G, Faries D, Lu P and Von Hoff DD (1995) Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13: 2842-2850
32. Rinaldi DA, Burris HA, Dorr FA, Rodriguez G, Eckardt SG, Fields SM, Woodworth JR, Kuhn JG, C. L, Clark G, Lu P and Von Hoff DD (1996) A phase I evaluation of LY231514, a multitargeted antifolate, administered every 21 days. Proc ASCO 15: 1559
33. Rusthoven J, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B and Iglesias J (1997) A phase II study of the multi-targeted antifolate LY231514 in patients with advanced non-small cell lung cancer. Am Soc Clin Oncol 16: abstract 1728
34. Schultz RM (1995) Newer antifolates in cancer therapy. In Progress in Drug Research, 44, Jucker E. (ed.), pp. 129-157, Birkhauser: Basle
35. Shih C, Chen VJ, Gossett LS, Gates SB, Mackellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Bearsley GP, Kohler W, Ratnam M and Schultz RM (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-1123
36. Smith IE, Miles DW, Coleman RE, Lind MJ, McCarthy S and Chick J (1997) Phase II study of LY231514 (MTA) in patients (pts) with locally recurrent or metastatic breast cancer (LR/MBC) - an interim report. Am Soc Clin Oncol 16: abstract 671
37. Strong WB, Tendler SJ, Seither RL, Goldman D and Schirch V (1990) Purification and properties of serine methyltransferase and C1-tetrahydrofolate synthase from L1210 cells. J Biol Chem 265: 12149-12155
38. Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo L, Jannatipour NJ and Moran RG (1992) A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3.4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl(ethyl] benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35: 4450-4454
39. Taylor IW, Slowiaczek P, Francis PR and Tattersall MHN (1982a) Purine modulation of methotrexate cytotoxicity in mammalian cell lines. Cancer Res 42: 5159-5164
40. Taylor IW, Slowiaczek P, Francis PR and Tattersall MHN (1982b) Biochemical and cell cycle perturbations in methotrexate-treated cells. Mol Pharmacol 21: 204-210
41. Trent DF, Seither RL and Goldman ID (1991) Compartmentation of intracellular folates. Biochem Pharmacol 42: 1015-1019
42. Webber S, Bartlett CA, Boritzki TJ, Hilliard JA, Howland EF, Johnston AL, Kosa M, Margosiak SA, Morse CA and Shetty BV (1996) AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother Pharmacol 37: 509-517
43. Wilson SD and Horne DW (1983) Evaluation of ascorbic acid in protecting labile folic acid derivatives. Proc Natl Acad Sci USA 80: 6500-6504